- Joint and Adjunct Faculty
Ph.D. in Biochemistry, University of California Berkeley
Genomic and genetic analysis of human traits and diseases.
Richard Myers, PhD, is president and scientific director at HudsonAlpha. Myer’s lab focuses on applying functional genomics and genetics approaches to understanding how genes and regulatory regions contribute to basic biology, human disease, responses to the environment and population genetics.
PhD in Pharmacology, University of Iowa
Genomics, common human disease
Howard Jacob, PhD, uses molecular genetics to understand complex, multifactorial disease. As executive vice president for genomic medicine at HudsonAlpha, Jacob brings together genome sequencing, bioinformatics and basic research to make a clinical diagnosis possible for patients.
MD, George Washington University School of Medicine
Human clinical genetics
David Bick, MD, PhD, is a clinical geneticist with more than 20 years experience diagnosing and treating children with genetic disorders. Bick is the medical director of the Clinic for Genomic Medicine on the HudsonAlpha campus.
Ph.D. in Biochemistry and Molecular Biology, Emory University
Epigenomic analysis of complex human traits and diseases
Devin Absher, PhD, uses the epigenome to study complex diseases and traits, especially autoimmune disease, cardiovascular disease, cancer and aging.
PhD in Genetics, Imperial College, London, UK
Clinical and translational use of genomic data
Liz Worthey, PhD, uses genomics and informatics to define the genetic underpinnings of human disease. In addition to her research goals, as the director of software development and informatics, she leads her team in supporting the informatics goals of the institute as well as the clinical mission to provide definitive diagnoses for patients.
M.D. and Ph.D. in pathology, University of Washington, Seattle
Genetic architecture of morphologic variation
Greg Barsh, PhD, MD, studies the genetic mechanisms that underlie differences in individual appearance and that could give new insight into both basic biology and human disease.
Ph.D. in Genetics, Stanford University
Human Genetics and Genomics
Greg Cooper, PhD, researches the structures, functions and evolutionary histories of human genomes, with an emphasis on applying genomic approaches to study human disease.
Ph.D. in Microbiology, University of Leeds, United Kingdom
Genomic resource development for plants
Jane Grimwood, PhD, co-directs the Genome Sequencing Center at HudsonAlpha, managing one of the few centers in the world that produces, analyzes and interprets genomic data on economically important plant and organism species to improve crop breeding and other agricultural practices.
B.S. in computer science, B.S. in biology, North Central College
Whole genome sequencing and assembly, population genomics
Jeremy Schmutz co-directs the Genome Sequencing Center at HudsonAlpha, managing one of the few centers in the world that produces, analyzes and interprets genomic data on economically important plant and organism species to improve crop breeding and other agricultural practices.
M.D., SuZhou Medical College, China; Ph.D. University of Alabama at Birmingham
Technology development to advance medical science
Jian Han, MD, PhD, focuses on developing integrated solutions for molecular differential diagnosis and mapping the personalized immunorepertoire.
MD, Comenius University, Martin, Czechoslovakia
PhD in Physiology, Comenius University, Bratislava, Czechoslovakia
Genomics, Common Human Diseases
The ultimate goal for personalized genomic medicine is tailoring treatment. Because we expect the majority of patients to have a unique sequence variant, tailoring treatment for patients with rare disease will require validation nominated sequence variants using different molecular biology approaches. In the validation process, the Lazar lab will utilize primary patients or commercially available human cell lines for different cellular assays or vertebrate model system using gene editing to generate and functionally test the variant of interest. The goal of Lazar’s work is to develop a functional screening program to rapidly test variants or genes identified in individual clinical cases and testing potential treatment modalities
PhD in Bioethics, University of Sydney, Sydney, NSW Australia
Genomics and Ethics
Kim Strong, PhD, is a genetics-trained bioethicist, a scientist who studies the application and limits of empirical ethics, particularly as it relates to contentious and emerging genetic technologies.
Ph.D. in Genetics and Molecular Biology, Emory University
Educational outreach relating to genetics, genomics and biotechnology
Neil Lamb, PhD, oversees all educational programming developed at HudsonAlpha as vice president for educational outreach. Lamb creates innovative teacher training, student experiences, public enrichment, classroom kits and digital resources that re-shape how science education is delivered.
Ph.D. in Genetics, Stanford University
Sara Cooper, PhD, focuses on combining metabolomics with genomics and applying that data to pancreatic and ovarian cancer.
Ph.D. in Biochemistry, Emory University
Technology development and automation, informatics, genomic variation
Shawn Levy, PhD, uses high performance genotyping and sequencing technologies to support projects from plant and animal phylogenetic studies to translational and clinical based projects at the Genomic Services Laboratory and the Clinical Services Laboratory.
PhD in Cell Biology, University of British Columbia, Canada
Molecular mechanisms of sarcomagenesis.
Le Su, PhD, has been actively involved in sarcoma research for nearly ten years. As a junior fellow at HudsonAlpha, his major focus is on chromosomal translocation-associated sarcomagenesis in children and young adults.
M.D., University of Ibadan, Nigeria; Ph.D., Biological Sciences in Public Health, Harvard University
Cancer Genomics, Infection-related cancers; Women’s cancers; Biomarkers for early detection of cancers and disease progression
In the Ojesina Lab, we seek to answer two big questions: (i) what are the genomic events that facilitate the progression of pre-malignant states to cancer, (ii) how do infections synergize with genomic alterations to cause cancer? Our work lies at the nexus of translational genomics, integrative molecular epidemiology, oncology, infectious disease, and global health, with a primary focus on infection-related cancers (including HIV-associated malignancies) and women’s cancers. We integrate high throughput sequencing with functional experiments in primary tissues and cell lines to investigate the mechanisms by which infections synergize with genomic and transcriptomic alterations to facilitate the tumor initiation, progression, response to therapy, recurrence and patient prognosis. We anticipate that this work will have translational impact by facilitating the development of diagnostic biomarkers and predictive models for early detection, prevention and treatment of various cancers, in local and global contexts.
M.D., Cornell University and Ph.D. in Genetics and Cell Biology, Rockefeller University
Genetics and treatment of neurofibromatosis type 1; Genetics and genomics education; Integration of genetics into medical practice
Dr. Korf completed his undergraduate studies and MD at Cornell University and received his PhD in genetics and cell biology from Rockefeller University. He then did training in pediatrics, child neurology, and genetics at Children’s Hospital, Boston, and is board certified in all three areas, as well as clinical cytogenetics and clinical molecular genetics. He served as clinical director and associate chief of the Children’s Hospital, Boston Division of Genetics until 1999, when he assumed the role of medical director of the Harvard-Partners Center for Genetics and Genomics. In 2003 he moved to University of Alabama at Birmingham, where he is the Wayne H. and Sara Crews Finley Chair in Medical Genetics, chair of the Department of Genetics, and director of the Heflin Center for Genomic Sciences. He also is co-director, of the UAB-HudsonAlpha Center for Genomic Medicine. Dr. Korf is past president of the Association of Professors of Human and Medical Genetics and of the American College of Medical Genetics and Genomics and currently is president of the ACMG Foundation for Genetic and Genomic Medicine. He has served on the Liaison Committee on Medical Education and the Board of Scientific Counselors of the National Cancer Institute and of the National Human Genome Research Institute at the NIH. Dr. Korf is author of Human Genetics and Genomics, co-author of Medical Genetics at a Glance, and co-editor ofCurrent Protocols in Human Genetics and Emery and Rimoin’s Principles and Practice of Medical Genetics. His research focus is the genetics and treatment of neurofibromatosis type 1 and he also has a major interest in genetics and genomics education and the integration of genetics into medical practice.
Ph.D. in Molecular and Cellular Biology, University of Minnesota
Function of regulatory regions of genome in human genome and human genetic diseases
The Mendenhall lab works to define the function of the regulatory or non-coding regions of the genome. These regions control how genes are turned on or off in the appropriate cells of our bodies. The lab focuses on developing methods to define what determines a functional regulatory region, investigating how the DNA sequence establishes these regions and understanding how variation in human DNA can alter this regulation to produce human traits and human genetic diseases. This requires the lab to develop and use specific synthetic biology tools, including customizable DNA binding proteins (TALEs and Crispr/Cas), synthetic DNA libraries and next-generation sequencing to assign biological functions to non-coding regions of the genome.
Ph.D., in Genetics, University of California, Berkeley
Prevention and treatment of Parkinson’s disease and Alzheimer’s disease
The Payami Lab is working towards prevention and treatment of Parkinson’s disease. PD is not a single disease: there are a myriad of genetic and environmental factors involved. The Payami lab is interested in the genes that interact with environmental risk factors – the goal being to predict who is at risk and what they should avoid; and also the genes that determine efficacy and toxicity of drugs for preventive and treatment – so that treatment can be personalized for maximum benefit for each individual. While we are on fast track for effective prevention and treatment, we are also interested in gaining a deep understanding of how the disease develops, why it progresses, why it affects so many systems of the body (physical and cognitive, psychiatric, digestive), and how best to halt it.
Ph.D. in Ecology and Evolution, Stony Brook University
Ecological effects on speciation genetics and genomics
The Matzkin lab investigates how the ecology of a species shapes patterns of variation (from genes to genomes), how populations adapt to environmental shifts and the implication of ecological adaptation in the process of speciation. The lab focuses on a group of cactophilic Drosophila that inhabit the deserts of North America. These Drosophila species are an excellent system to study since their ecology is well understood and researchers can perform many genetic, genomic, manipulative and life history experiments on them. The lab concentrates on studying the genetic basis of adaptation; analyzing genome evolution via the sequencing and assembly of several cactophilic Drosophila species; examining the role of gene expression changes in evolution; understanding the effects of ecological adaptation in behavioral evolution and its effects on reproductive isolation; investigating speciation genetics/genomics; and exploring the relationship between molecular, expression and life history variation and evolution.